About Gilead
Gilead is a company based in Foster City (United States) founded in 1987. The company has 17,600 employees as of December 31, 2024. Gilead has completed 21 acquisitions, including Arcellx, Arresto BioSciences and CGI Pharmaceuticals. Gilead offers products and services including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments. Gilead operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Foster City, United States
- Employees 17600 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gilead Sciences, Inc.
-
Annual Revenue
$28.73 B (USD)6.17as on Dec 31, 2024
-
Net Profit
$480 M (USD)-91.53as on Dec 31, 2024
-
EBITDA
$13.43 B (USD)7.96as on Dec 31, 2024
-
Latest Funding Round
$290 K (USD), Post-IPO
Jan 27, 2025
-
Investors
Wealth Enhancement
& 8 more
-
Employee Count
17600
as on Dec 31, 2024
-
Investments & Acquisitions
Arcellx
& 20 more
-
Acquired by
& 1 more
(Apr 19, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Gilead
Gilead is a publicly listed company on the NASDAQ with ticker symbol GILD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Gilead
Gilead offers a comprehensive portfolio of products and services, including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments.
Treatments for HIV, viral hepatitis, and emerging viruses
Therapies for cancer and related conditions
Medicines for inflammatory diseases and disorders
People of Gilead
Unlock access to complete
Unlock access to complete
Leadership Team
294 people
Software Development Team
183 people
Senior Team
62 people
Legal and Compliance
41 people
Data Analysis and Operations Team
38 people
Human Resources and Administration
38 people
Operations Team
38 people
Finance and Accounting
36 people
Unlock access to complete
Funding Insights of Gilead
Investors in Gilead
Gilead has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Wealth Enhancement, DriveWealth and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors including healthcare are invested in by IFM Investors.
|
Locked | Locked | Locked | |
|
Cloud-based API solutions for embedded investing are provided online.
|
Locked | Locked | Locked | |
|
Investment management services are offered by Bellevue in Switzerland.
|
Locked | Locked | Locked |
Investor details for Gilead
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gilead
Gilead has strategically engaged in corporate development activities, having acquired 21 companies. Notable acquisitions include Arcellx, Arresto BioSciences and CGI Pharmaceuticals.
Investment portfolio details for Gilead
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for chronic immune-mediated diseases are developed by Ouro Medicines.
|
Locked | Locked | 2024 | Locked | |
|
Small-molecule therapeutics for immuno-oncology diseases are developed.
|
Locked | Locked | 2021 | Locked | |
|
Developer of therapeutics for auto-immune diseases
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Gilead
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Gilead
Detailed financials for Gilead
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gilead Comparisons
Peer comparison for Gilead
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gilead
Gilead operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Gilead
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gilead
Complete news archive for Gilead
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gilead
Gilead was founded in 1987 and raised its 1st funding round 23 years after it was founded.
Gilead is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
As of Dec 31, 2024, the latest employee count at Gilead is 17,600.
Annual revenue of Gilead is $28.73B as on Dec 31, 2024.
Founded in 1987 and headquartered in Foster City, United States, Gilead operates as a research-based biopharmaceutical company. Innovative medicines are discovered, developed, and commercialized to address unmet medical needs in HIVAIDS, liver diseases, and cancer. Key developments include the Lenacapavir capsid inhibitor for HIV and the Selgantolimod TLR-8 agonist for HBV. In 2022, annual revenues of 27.28 billion and net profit of 4.59 billion were recorded.
Gilead's top competitors include Merck, Roivant Sciences and AbbVie.
Gilead offers Antiviral Medicines, Oncology Drugs, and Inflammation Treatments.
Yes, Gilead is publicly traded on NASDAQ under the ticker symbol GILD.
Gilead has made 21 acquisitions, including Arcellx, Arresto BioSciences, and CGI Pharmaceuticals.
Gilead has 9 investors. Key investors include Wealth Enhancement, DriveWealth, Citadel, Bellevue, and European Union.
The ticker symbol of Gilead is GILD on NASDAQ.